How to Choose Laboratory & Research Equipment

# How to Choose Laboratory & Research Equipment

*A procurement-focused guide to capital purchasing for clinical, R&D, and core-facility labs — covering CLIA fit, total cost of ownership, regulatory exposure, and refurbished/lease tradeoffs.*

## What this is and who buys it

"Laboratory and research equipment" is a broad capital-asset category that spans analytical instruments (HPLC/UPLC, GC/MS, LC/MS, ICP-MS, spectrophotometers), sample-prep tools (centrifuges, shakers, thermal cyclers, homogenizers), environmental units (incubators, ULT freezers, biosafety cabinets, stability chambers), and the consumables platforms that feed them. Buyers are typically lab managers, principal investigators, core-facility directors, biomedical engineers, and procurement officers — usually purchasing either to stand up a new lab, replace end-of-life assets, or expand a validated test menu.

The decision drivers vary sharply by setting. A hospital reference lab buying a chemistry analyzer is governed by CLIA complexity rules and CAP inspection expectations; an academic proteomics core buying an Orbitrap is more concerned with duty cycle, vendor application support, and shared-user scheduling; a CDMO buying a stability chamber is constrained by 21 CFR Part 11 and ICH Q1A. 
Almost half of all tests listed in the FDA CLIA database are classified as moderately complex
, which means most clinical buyers will sit in the "non-waived" regime and inherit its proficiency-testing, QC, and personnel obligations.

## Key decision factors

**Match instrument complexity to your test menu and CLIA tier.** Every clinical instrument purchase has to be reconciled against the CLIA certificate the lab holds — or intends to hold. 
The type of CLIA certificate a laboratory obtains depends upon the complexity of the tests it performs, and CLIA regulations describe three levels of test complexity: waived tests, moderate complexity tests, and high complexity tests.
 Critically for buyers writing specs for laboratory-developed tests, 
tests developed by the laboratory or modified from the approved manufacturer's instructions default to high complexity according to the CLIA regulations
. That single rule routinely catches buyers off guard when a "moderate complexity" analyzer is reconfigured for an in-house assay and silently pulls the lab into high-complexity personnel and QC requirements.

**Open vs. closed reagent systems.** Closed (proprietary) consumables platforms — common in immunoassay, molecular diagnostics, and clinical chemistry — lock the lab into a single supplier for the asset's life. Open-channel systems give flexibility for LDTs and method development but transfer validation burden to the lab. Model the five-year reagent and consumable spend before committing; on many analyzers, reagents will outspend the capital cost by year three.

**LIS/EMR integration.** Confirm bidirectional HL7, ASTM, or LIS2-A2 support in writing, with a named middleware partner where applicable. Clinical labs should ask whether interfaces are validated for the specific LIS/EMR build (e.g., Epic Beaker, Cerner Millennium, SoftLab). Interface fees of $5,000–$25,000 per instrument are common and rarely appear on the initial quote.

**Total cost of ownership beyond sticker price.** A useful rule of thumb for analytical instruments is that the five-year TCO runs 1.8x–2.5x the capital cost once preventive maintenance, columns/lamps/electrodes, qualification gases, and calibration are included. Build a TCO model before short-listing — not after.

**Calibration traceability and uncertainty budget.** For accredited labs this is non-negotiable. 
Equipment requirements mandate that all equipment used for testing be calibrated and maintained, with calibration records traceable to national or international measurement standards, and that all measurement results be traceable to the International System of Units (SI) through an unbroken chain of calibrations.
 In the U.S., that chain typically terminates at NIST. 
Typically, the shorter the chain between your laboratory and a national metrology institute, the smaller the uncertainty in measurement you can expect to see.
 Ask the vendor whether calibration certificates ship with each unit and who their accredited calibration provider is.

**Parts availability and service network.** Confirm — contractually — the OEM's parts-support window after end-of-sale. Seven to ten years is typical for analyzers and chromatography systems; less for high-end MS platforms where manufacturers cycle architectures every four to five years. A short parts horizon makes the depreciation schedule unrealistic.

**Scalability and upgrade path.** For modular platforms (autosamplers, detectors, sequencer flow cells), confirm forward compatibility in writing. "Upgradeable" frequently means "upgradeable for a fee" or "upgradeable to a SKU we plan to discontinue."

**Compatibility with consumables and reagents.** Sole-source consumables are a procurement risk flag, particularly post-2020 supply-chain disruptions. Where possible, prefer instruments that accept consumables from at least two qualified suppliers.

## What it costs

Pricing in this category is unusually wide because the category itself spans six-figure benchtop instruments and seven-figure mass spectrometers. Public list prices are uncommon; most quotes are negotiated and bundled with service, training, and consumables credits.

- **Entry tier — $2,000 to $50,000.** Benchtop centrifuges, microplate readers, CO₂ incubators, basic UV-Vis spectrophotometers, analytical balances, standard 96-well thermal cyclers, pipettes, and shakers. These are typically Class I devices in clinical contexts and often purchased on capex thresholds that don't require committee review.
- **Mid tier — $50,000 to $250,000.** HPLC/UPLC systems, single-quadrupole GC/MS, qPCR platforms, mid-range flow cytometers, ULT freezers, Class II biosafety cabinets, and refurbished triple-quadrupole LC/MS. Most clinical 510(k)-cleared analyzers also live here.
- **Premium tier — $250,000 and above.** New triple-quadrupole LC/MS, Q-TOF, Orbitrap, MALDI-TOF, NGS sequencers, and FT-MS. Public secondary-market listings for mass spectrometry routinely span $50,000 to over $2.5M depending on platform, age, and configuration. Where vendors decline to publish list prices (the norm for high-end MS and NGS), buyers should request three reference quotes from peer institutions under NDA rather than relying on the vendor's own benchmarks.

Where specific bands aren't published — true for most premium analytical instruments — that is the market reality, not an oversight: pricing is configuration-dependent and almost always negotiated.

## Common use cases

- Hospital and reference clinical labs running CLIA moderate- and high-complexity testing under CAP or Joint Commission inspection.
- Pharma and biotech R&D groups performing drug discovery, bioanalysis, and QC release testing under 21 CFR Part 11.
- Academic core facilities (proteomics, genomics, cytometry, imaging) operating chargeback models across multiple PIs.
- Environmental, food-safety, and cannabis testing labs running EPA, AOAC, or state-mandated methods.
- CROs and CDMOs operating under GLP and GMP.
- Forensic toxicology and public-health laboratories.

## Regulatory and compliance notes

Clinical IVDs and laboratory instruments used for diagnostic purposes are regulated by FDA's CDRH. Devices fall into Class I, II, or III based on risk, with Class II covering most cleared analyzers under 510(k) special controls and Class III requiring PMA. 
Within FDA, CLIA categorization is conducted by the Center for Devices and Radiological Health (CDRH).
 
Test systems receive an initial CLIA categorization from the FDA after the test system is cleared/approved/licensed/granted following review of a marketing submission.


Buyers should also understand the practical scope difference between waived and non-waived testing. 
Nonwaived testing is subject to inspection, and must meet the CLIA quality system standards, such as those for proficiency testing, quality control and assessment, and personnel requirements; the standards for moderate and high complexity testing differ only in the personnel requirements.
 The personnel delta is the most expensive surprise in the category — moving from moderate to high complexity often requires a qualified technical supervisor on staff.

For non-clinical testing and calibration laboratories, ISO/IEC 17025:2017 accreditation is the dominant framework. 
ISO 17025 requires that all equipment relevant to the testing and calibration processes must be calibrated and maintained appropriately to ensure the validity and reliability of the results, with calibration procedures planned, documented, and defined in a way that they can be replicated, and the equipment checked at specified intervals against certified standards traceable to international or national measurement standards.
 Risk management documentation should follow ISO 14971 where applicable; electrical safety follows IEC 61010 for general lab equipment or IEC 60601-1 where the device is patient-contacting. Quality systems for finished medical devices fall under 21 CFR Part 820, with adverse-event reporting under 21 CFR Part 803. Connected instruments handling PHI trigger HIPAA Security Rule (45 CFR 164.300) controls.

## Service, training, and total cost of ownership

Plan IQ/OQ/PQ qualification at install for any instrument supporting GxP or accredited workflows, and budget for it explicitly — vendors frequently quote IQ but charge separately for OQ and PQ. Annual preventive maintenance contracts on analytical instruments (HPLC, GC, MS) typically run 8–12% of capital cost. Calibration cadence is risk-based: balances and pipettes every 6–12 months, centrifuges and temperature-controlled units annually, analytical instruments per validated method.

Useful-life expectations for budgeting and depreciation:

- 7–10 years for clinical analyzers and chromatography systems.
- 10–15 years for centrifuges, incubators, and biosafety cabinets (with periodic recertification).
- 5–7 years for ULT freezers before compressor replacement becomes economically marginal.

Training is routinely under-budgeted. Confirm whether the quote includes operator training, application-scientist time, and method-development support, or only a one-day orientation. For high-complexity instruments, factor in a second round of training when staff turn over in years two and three.

## Red flags to watch for

- Vendor cannot produce a 510(k) number, CE mark, or CLIA categorization letter for clinical use cases.
- Service contract carves out the detector, lamp, column, electrode, or other consumable-wear items that drive most repair calls.
- Sole-source proprietary reagents with no published cost-per-test schedule or contractual price-increase cap.
- "Refurbished" units sold without documented OQ/PQ or a written warranty.
- Quoted parts lead times exceeding four weeks with no loaner program.
- No documented audit trail or user-permission controls on instruments destined for GLP, GMP, or 21 CFR Part 11 environments.
- Sales configurations richer than the validated test menu actually requires — over-specification is a common failure mode.
- Reliability data the vendor refuses to support with named references or published ECRI/MD Buyline benchmarks.

## Questions to ask vendors

1. Provide the FDA 510(k) clearance number, CLIA categorization, and CE-IVD status (if applicable), along with the predicate device used.
2. What is the total five-year cost of ownership including PM contract, calibration, expected consumables (columns, lamps, electrodes, gases), and utility requirements?
3. What is your guaranteed parts-availability window after end-of-sale, and what is the average mean-time-to-repair in our region?
4. Will you provide IQ/OQ/PQ documentation, and is the system 21 CFR Part 11 compliant out of the box or via add-on module?
5. Which LIS/middleware interfaces (HL7, ASTM, LIS2-A2) are validated against our specific LIS build, and what is the cost of bidirectional integration?
6. Provide three reference customers running our throughput and test menu, along with uptime data from the last 12 months.
7. What is the difference in price, warranty, and performance specification between a new unit, an OEM-certified refurbished unit, and a lease?
8. Are reagents and consumables open-channel or proprietary, and will you contractually cap annual reagent price increases?
9. What calibration certificates ship with the instrument, and is your calibration provider ISO/IEC 17025 accredited with traceability to NIST or another national metrology institute?
10. What are the documented end-of-life and end-of-support dates for the platform and its software?

## Alternatives — refurbished, lease vs. buy, service contracts

**Refurbished vs. new.** OEM-certified refurbished instruments typically run 40–60% of new-list pricing, with the range driven by age, condition, location, and platform demand. As a representative data point, a new triple-quadrupole LC/MS commonly quotes between $350,000 and over $500,000 depending on configuration, while a certified refurbished TQ LC/MS with third-party warranty more often falls in the $75,000–$150,000 band. The tradeoff is shorter remaining service life and higher end-of-support exposure in exchange for 50–70% capital savings. For regulated workflows, insist on OEM-certified refurbishment with documented OQ/PQ and a minimum one-year warranty.

**Lease vs. purchase.** Operating leases shift technology-obsolescence risk to the lessor — a meaningful benefit for sequencers and high-end MS, where platforms turn over every four to five years — but typically cost 15–25% more across the term. Capital leases or outright purchase make more sense for stable platforms (centrifuges, incubators, balances, biosafety cabinets) with 10+ year service lives.

**OEM service vs. third-party (ISO) vs. in-house.** Full OEM contracts run 8–12% of list price annually but include software updates and priority parts. Multi-vendor third-party service organizations typically save 20–40% but may not cover firmware updates or proprietary diagnostics. In-house biomedical engineering is economically viable only for high-volume identical fleets — for example, 20+ identical centrifuges or a standardized incubator pool — where training amortizes across the asset base.

**Reagent rental and "cost-per-test" models.** Common in clinical chemistry and immunoassay, the vendor places the instrument at zero or low capital cost and recovers margin through reagent pricing. Useful for cash-constrained labs but contractually unforgiving: underutilization typically triggers minimum-purchase penalties. Forecast volumes conservatively and read the minimums clause before signing.

## Sources

1. FDA — Overview of IVD Regulation. https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation
2. FDA — CLIA Categorizations. https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clia-categorizations
3. FDA — Administrative Procedures for CLIA Categorization (Guidance). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/administrative-procedures-clia-categorization
4. CDC — CLIA Test Complexities. https://www.cdc.gov/clia/php/test-complexities/index.html
5. CMS — Categorization of Tests. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments/cartegorization
6. ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
7. NIH SEED — Regulatory Knowledge Guide for In Vitro Diagnostics. https://seed.nih.gov/sites/default/files/2024-04/Regulatory-Knowledge-Guide-for-In-Vitro-Diagnostics.pdf
8. ISOBudgets — Measurement Traceability: Complying with ISO 17025 Requirements. https://www.isobudgets.com/measurement-traceability-complying-iso-17025-requirements/
9. RJ Quality Consulting — ISO 17025 Equipment Requirements. https://rjqualityconsulting.com/iso-17025-equipment-requirements/
10. Transcat — 17025 Accreditation: Calibration Requirements White Paper. https://www.transcat.com/17025-accreditation-calibration-requirements-white-paper
11. Siemens Healthineers — CLIA Moderate Complexity Testing Guide. https://www.siemens-healthineers.com/en-us/point-of-care-testing/clia-moder